TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05891314

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botox Injectable Product
Description: one group will have botox injection in the internal sphincter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botox Injectable Product
Description: one group will have botox injection in the internal sphincter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal sphincterotomy
Description: this group will have internal sphincterotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal sphincterotomy
Description: this group will have internal sphincterotomy
Study: NCT05651451

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser acupuncture
Description: 24 activated laser acupuncture treatments. Treatments was performed 3 times per week for 8 weeks.Laser acupuncture was applied withwavelength of 810 nm, power output of 150 mW in continuous wave mode and energy density laser of 4 J/cm2 with irradiation time 3 min/point

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: energy-restricted diet
Description: All post-menopausal women followed an energy-restricted diet for 8 weeks. Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: energy-restricted diet
Description: All post-menopausal women followed an energy-restricted diet for 8 weeks. Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E
Study: NCT06039826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone
Description: Administered orally
Study: NCT04861467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: IV
Study: NCT04998552

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cyberknife
Description: 5-10 Gy/fraction.Average of 45 minutes every other day for a total of 5 sessions (1.5-2 weeks).
Study: NCT05974033

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Stenting plus medical therapy
Description: Patients randomized to intervention group received the percutaneous transluminal balloon angioplasty with stenting within 5 days after randomization, and loading dose of aspirin and clopidogrel was allowed. Received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy alone
Description: Medical therapy alone: received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after randomisation.
Study: NCT05983861

Intervention type: DIAGNOSTIC_TEST
Intervention: Identification o Multi Drug Resistant Bacteria
Description: Identification o Multi Drug Resistant Bacteria

Intervention type: DIAGNOSTIC_TEST
Intervention: Identification o Multi Drug Resistant Bacteria
Description: Identification o Multi Drug Resistant Bacteria
Study: NCT04503681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced compassion video
Description: Added five additional sentences to the standard introduction video. Those five sentences were compassion-focused statements. The compassionate statements added to the enhanced compassion video were based on the results of a recent systematic review of clinician compassionate behaviors, which found incorporating statements of support, acknowledgement, patient's perspective, emotion naming, and validation increased patient perception of compassion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard introduction video
Description: Standard introduction video sent to a new patient via email introducing the new patient to the cancer center prior to the initial consultation.
Study: NCT05919680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NST-6179 Part A
Description: Once daily (QD) oral administration of 800mg (32 mL solution) of NST-6179 for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NST-6179 Part B
Description: Once daily (QD) oral administration of 1200mg of NST-6179 for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matched Placebo
Description: Matched placebo for administration in Part A or Part B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matched Placebo
Description: Matched placebo for administration in Part A or Part B
Study: NCT06176872

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Computed Tomography Angiography
Description: Non-invasive imaging of the heart, the greater vessels and the coronary arteries using computed tomography.
Study: NCT04921384

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% normal saline, intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Solution for infusion, intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Solution for infusion, intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eptinezumab
Description: Solution for infusion, intravenously
Study: NCT04139577

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: FMT- Oral Study Drug, predetermined dosage and timings, up to 2 cycles
Study: NCT04984876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ligelizumab
Description: Subcutaneous injection once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ligelizumab
Description: Subcutaneous injection once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ligelizumab
Description: Subcutaneous injection once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ligelizumab
Description: Subcutaneous injection once every 4 weeks
Study: NCT04334408

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fremanezumab
Description: Subjects will receive a single dose total 225 mg (1 injection of 225 mg per 1.5 mL injection) followed by a single dose of 225 mg (1 1.5mL injection) at four week intervals. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fremanezumab
Description: Subjects will receive a single dose total 225 mg (1 injection of 225 mg per 1.5 mL injection) followed by a single dose of 225 mg (1 1.5mL injection) at four week intervals. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections during the run in and washout serves as the control condition. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo injections during the run in and washout serves as the control condition. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
Study: NCT04958005

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Enzim linked immunoabsorbant assay

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Enzim linked immunoabsorbant assay
Study: NCT04378751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision aid video
Description: Decision aid video

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Genetic counseling informational brochure
Description: Genetic counseling informational brochure
Study: NCT06207994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow TR
Description: The width of the PRICO SpO2 TR is set to 3% SpO2.
Study: NCT06141486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frexalimab
Description: SAR441344 Solution for IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRI contrast-enhancing agents
Description: IV, as per respective label
Study: NCT04984876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ligelizumab
Description: Subcutaneous injection once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection once every 4 weeks
Study: NCT05557552

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: standar thoracic RT dose
Description: All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4-6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with standard dose thoracic radiotherapy of 60 Gy/30Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: decreased thoracic RT dose
Description: All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4-6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with decreased thoracic radiotherapy of 50Gy/25Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.
Study: NCT06581497

Intervention type: DRUG
Intervention: ICIs
Description: ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines.

Intervention type: PROCEDURE
Intervention: ICIs+MWA
Description: ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines. All patients, except for those enrolled in ICIs, should also undergo MWA treatment.
Study: NCT05649722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Palmitil Inhalation Powder
Description: Oral inhalation using a capsule-based dry powder inhaler device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo inhalation using a capsule-based dry powder inhaler device.
Study: NCT06207994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shifted TR
Description: The lower and the upper limits of the PRICO SpO2 TR are increased by 1% SpO2.
Study: NCT05385887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 500 mg
Description: One tablet of 500mg Ciprifloxacine, twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 500 mg
Description: One tablet of 500mg Metronidazole, three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT05165940

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Care Coordination Treatment as usual with a VA mental health treatment coordinator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Health Services Intervention
Description: The experimental care coordination intervention begins with a 60-minute in-person session and continues with regular, brief contacts between the Veteran and clinician. During the first session, the clinician and Veteran will (1) discuss the Veteran's beliefs about their presenting problem; (2) collaboratively identify SMART goals; (3) discuss treatment options; (4) use shared decision-making to match treatment to SMART goals; (5) develop criteria to evaluate treatment progress; and (6) manage treatment expectations. During follow-up sessions, the clinician and Veteran will reflect on treatment progress, make appropriate updates to SMART goals, and re-evaluate barriers to CPT or PE.
Study: NCT05858671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fenugreek Seed Tea
Description: Fenugreek seeds will be delivered at a dose of 5g/day, drunk as a tea (2.5g/per tea bag), p.o. twice a day at a 12-hour interval) for 8 weeks (56 days). The tea bags will be brewed in a cup (200ml) of boiled hot water for 10 minutes before drinking. This will be self-administered by the subjects, twice a day at a 12-hour interval.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Black Tea
Description: A control black tea (2.5g/bag), self-administered by the subjects, twice in a day at a 12-hour interval.
Study: NCT06528743

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases.
Description: Patients will receive RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases. Enrolled patients will receive a fractionation scheme with increasing break length.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases.
Description: Patients will receive RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases. Enrolled patients will receive a fractionation scheme with increasing break length.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases.
Description: Patients will receive RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases. Enrolled patients will receive a fractionation scheme with increasing break length.
Study: NCT04633811

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Oxalate Diet before Weight Loss
Description: Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 6 days. 2 x 24 hour urines will be collected on days 3 and 4.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral load of oxalate and sucralose before Weight Loss
Description: Subjects will ingest 100mg carbon-13 oxalate, and 2 grams of sucralose on day 5 of the 6-day low oxalate diet phase. Following the oral load, blood and urine will be collected every 30 minutes and hourly, respectively

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Optifast VLCD Program
Description: Subjects will go on a 10-week Intestive level Optifast VLCD weight loss program

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Optifast VLCD Transition Phase
Description: After completion of the 10-week Optifast VLCD Program, subjects will be weaned off the Optifast products for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Oxalate Diet after Weight Loss
Description: Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 11 days and collect 2 x 24 hour urines on days 8 and 9

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral load of oxalate and sucralose after Weight Loss
Description: Subjects will ingest 100mg carbon-13 oxalate, and 2 grams of sucralose on day 10 of the 11-day low oxalate diet phase. Following the oral load, blood and urine will be collected every 30 minutes and hourly, respectively
Study: NCT06176521

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Sacrohysteropexy and Sacrocolpopexy Surgeries Performed Without Mesh
Description: Comparison of pre and postoperative POP-Q values of the patients undergone Laparoscopic Sacrohysteropexy and Sacrocolpopexy SurgeriesWithout Using Mesh Comparison of pre and postoperative PISQ-12 scores of the patients undergone Laparoscopic Sacrohysteropexy and Sacrocolpopexy Surgeries Without Using Mesh
Study: NCT05901051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vonoprazan
Description: Potassium competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vonoprazan
Description: Potassium competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vonoprazan
Description: Potassium competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotics for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotics for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotics for H. pylori eradication
Study: NCT05291988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive S2S education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Immunochemical Test
Description: Receive FIT kit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary Studies
Study: NCT05945823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: TAS-120 20 mg tablets, oral; once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: TAS-120 20 mg tablets, oral; once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg once every 6-week-cycle, via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg once every 6-week-cycle, via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 4000 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m\^2 Q2W via bolus IV infusion followed by 2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.~2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.~2400 mg/m\^2 Q2W via continuous IV infusion, as part of mFOLFIRINOX chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 4000 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m\^2 Q2W via bolus IV infusion followed by 2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.~2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.~2400 mg/m\^2 Q2W via continuous IV infusion, as part of mFOLFIRINOX chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m\^2 Q2W via IV infusion, as part of mFOLFIRINOX or mFOLFOX6 chemotherapy. 2400 mg/m\^2 Q2W via continuous IV infusion, as part of mFOLFIRINOX chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m\^2 Q2W via IV infusion, as part of mFOLFIRINOX or mFOLFOX6 chemotherapy. 2400 mg/m\^2 Q2W via continuous IV infusion, as part of mFOLFIRINOX chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m\^2 Q2W as part of mFOLFIRINOX or mFOLFOX6 chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m\^2 Q2W as part of mFOLFIRINOX or mFOLFOX6 chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoleucovorin
Description: 200 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoleucovorin
Description: 200 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/m\^2 Q2W as part of mFOLFIRINOX chemotherapy.
Study: NCT05781347

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Energy to the LES (Stretta Procedure)
Description: The Stretta procedure is an endoscopic treatment performed under general anesthesia. It utilizes radiofrequency (RF) energy delivered to the lower esophageal sphincter (LES) and the gastric cardia to enhance the antireflux barrier.
Study: NCT05752903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine-propofol
Description: 1 microgram/kg dexmedetomidine+2.5 mg/kg propofol intravenous (IV) bolus, 0.5 microgram g/kg/h dexmedetomidine+2.5 mg/kg/h propofol infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine-Propofol
Description: 1 mg/kg ketamine+2.5 mg/kg propofol iv bolus, 0.25 mg/kg/h ketamine+2.5mg/kg/h propofol infusion
Study: NCT06178380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: For the experimental group:~Isokinetic training Antigravity treadmill Posturography~For the control group:~Patients will receive a standard rehabilitation prescription comprising:~Physiotherapy , muscle stretching and strengthening , proprioceptive exercises, and self-programmed
Study: NCT05855850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brainsway H4-Coil Deep TMS System
Description: Participants assigned to this arm will complete a 4-week course of 5 dTMS sessions per week (using the Brainsway H4-coil), for a total of 20 stimulation sessions. We will follow the standard Health Canada and FDA-approved protocol for depression: 18 Hz and 55 trains, for a total of 1980 pulses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brainsway H7-Coil Deep TMS System
Description: Participants assigned to this arm will complete a 4-week course of 5 dTMS sessions per week (using the Brainsway H7-coil), for a total of 20 stimulation sessions. We will follow the standard Health Canada and FDA-approved protocol for depression: 18 Hz and 55 trains, for a total of 1980 pulses.